Alanine for Liver Function (Alanine Aminotransferase (ALT) — Alanine Aminotransferase)

Table of Contents

1. Alanine Aminotransferase — The Enzyme Named After Alanine
2. Why Alanine Aminotransferase Is the Most Liver-Specific Routine Marker
3. The Normal Range Controversy (40 U/L vs 19/30 U/L)
4. Interpretation by Magnitude of Alanine Aminotransferase Elevation
5. The Aspartate Aminotransferase:Alanine Aminotransferase Ratio — Alcoholic vs Non-Alcoholic Patterns
6. Non-Alcoholic Fatty Liver Disease — The Global Liver Disease Epidemic
7. Drug-Induced Liver Injury (DILI)
8. Viral Hepatitis Pattern
9. Practical Workup of an Isolated Alanine Aminotransferase Elevation
10. The Alanine Load Test for Hepatic Function
11. Cautions
12. Key Research Papers
13. Connections
14. Featured Videos

Alanine Aminotransferase — The Enzyme Named After Alanine

Alanine aminotransferase (ALT, EC 2.6.1.2) is one of the two principal aminotransferases of clinical interest, the other being aspartate aminotransferase (AST, EC 2.6.1.1, historically SGOT). Both enzymes use pyridoxal-5-phosphate (the active form of vitamin B6) as cofactor and catalyze reversible transamination reactions. Alanine aminotransferase catalyzes:

L-alanine + alpha-ketoglutarate ↔ pyruvate + L-glutamate

This is the rate-limiting entry step for alanine's contribution to hepatic gluconeogenesis. In muscle, alanine aminotransferase runs the same reaction in the forward direction (consuming pyruvate and glutamate to produce alanine for nitrogen export); in liver, it runs in reverse (consuming alanine to produce pyruvate for gluconeogenesis). The directional preference depends on cell-specific concentrations of the four reactants and on the cell's gluconeogenic vs gluconeogenic-suppressed state.

Alanine aminotransferase exists in two isozymic forms in humans: ALT1 (cytosolic, encoded by GPT) and ALT2 (mitochondrial, encoded by GPT2). The cytosolic ALT1 is the predominant form in liver and the form that is measured on standard liver panels. The mitochondrial ALT2 is more highly expressed in muscle, heart, and brain — tissues where the alanine-shuttle role is less critical — and contributes only modestly to serum activity in healthy adults.

The historical name SGPT (serum glutamic-pyruvic transaminase) reflects the products of the reaction (glutamate and pyruvate) rather than the substrate (alanine). The shift to the alanine aminotransferase nomenclature occurred gradually through the 1980s and 1990s as the systematic IUPAC enzyme nomenclature became the international standard. Older patients and some European laboratories may still report SGPT; this is the same enzyme as alanine aminotransferase.

Back to Table of Contents

Why Alanine Aminotransferase Is the Most Liver-Specific Routine Marker

Alanine aminotransferase's clinical usefulness depends on two facts:

• Hepatocytes contain extremely high alanine aminotransferase concentrations — approximately 3,000-fold higher than serum concentrations. Even modest hepatocyte injury releases enough enzyme to produce measurable serum elevations within hours.
• Other tissues contain relatively little alanine aminotransferase — kidney, heart, and skeletal muscle contain detectable but much lower alanine aminotransferase activity. The serum alanine aminotransferase pool in a healthy adult therefore predominantly reflects hepatic origin.

Aspartate aminotransferase is the more revealing contrast. Aspartate aminotransferase is also abundant in liver, but is equally abundant in skeletal muscle, cardiac muscle, kidney, brain, and red blood cells. Hemolysis during phlebotomy can artifactually elevate aspartate aminotransferase. Vigorous exercise can elevate aspartate aminotransferase significantly. Acute myocardial infarction historically caused dramatic aspartate aminotransferase elevations (which is why aspartate aminotransferase was originally used as a cardiac marker before cardiac-specific troponins came along). All of these confounders are absent or markedly reduced for alanine aminotransferase.

The clinical inference is that an isolated alanine aminotransferase elevation almost always reflects hepatocyte injury, while an aspartate aminotransferase elevation must always be interpreted in light of possible non-hepatic sources. This is the basis for the diagnostic primacy of alanine aminotransferase in hepatology workups and for the aspartate aminotransferase:alanine aminotransferase ratio as a discriminator (see below).

There are a few specific exceptions worth mentioning:

• Severe muscle injury (rhabdomyolysis) can elevate alanine aminotransferase modestly due to release from skeletal muscle. The creatine kinase (CK) elevation will be the dominant finding and will dwarf the alanine aminotransferase changes.
• Inflammatory myopathies (polymyositis, dermatomyositis) can produce chronic mild alanine aminotransferase elevations from muscle origin. Creatine kinase, aldolase, and clinical features distinguish from primary liver disease.
• Celiac disease can produce mild alanine aminotransferase elevations through poorly understood gut-liver axis mechanisms; the elevations resolve on a gluten-free diet.
• Strenuous exercise within 24-48 hours of blood draw can mildly elevate both alanine aminotransferase and aspartate aminotransferase through muscle origin. Repeat testing after exercise abstinence clarifies.

Back to Table of Contents

The Normal Range Controversy (40 U/L vs 19/30 U/L)

The standard laboratory "normal range" for alanine aminotransferase is typically reported as up to 40 U/L (some labs use up to 35 U/L). These ranges were originally derived in the 1970s from blood donor populations that, in retrospect, included many subjects with subclinical non-alcoholic fatty liver disease and chronic viral hepatitis (then unrecognized). The result is that the "normal range" was set too high — many subjects within the reported normal range actually had liver pathology.

The Prati 2002 Annals of Internal Medicine study redefined healthy alanine aminotransferase ranges using a much more rigorously screened reference population (blood donors with no clinical or laboratory evidence of liver disease, no body mass index (BMI) above 25, no metabolic syndrome). The Prati cutoffs are:

• Men: upper limit of normal 30 U/L (not 40)
• Women: upper limit of normal 19 U/L (not 40)

The Prati cutoffs have not been universally adopted by clinical laboratories, partly because the implications are uncomfortable: applying the stricter cutoffs to the general population reclassifies a substantial fraction of presumably-healthy adults as having mildly abnormal alanine aminotransferase. The NHANES population data show that roughly 20-30% of US adults have alanine aminotransferase above the Prati upper limit, which corresponds well to the prevalence of non-alcoholic fatty liver disease established by hepatic ultrasound and biopsy studies.

The clinical practical implication is that an alanine aminotransferase of 35 U/L — clearly within the standard 40 U/L reporting cutoff — should not be reflexively dismissed as "normal," especially in a woman or in a patient with metabolic risk factors. The 2017 ACG Clinical Guideline (Kwo et al.) explicitly endorses the Prati cutoffs for clinical decision-making in the workup of liver disease, even when the local laboratory continues to report up to 40 U/L as "normal."

For patients tracking their own liver health, the practical rule of thumb is:

• Alanine aminotransferase below 19 (women) or 30 (men): truly normal, no further action needed unless other indicators warrant.
• Alanine aminotransferase 19-40 (women) or 30-40 (men): below the lab's reported upper limit but above the Prati cutoff. Reasonable trigger for a metabolic workup (lipids, hemoglobin A1c, body mass index, alcohol screen) and re-check in 6 months.
• Alanine aminotransferase 40-150 U/L: mildly elevated by any standard. Workup as described in the practical workup section below.
• Alanine aminotransferase >150 U/L: moderately elevated. Always abnormal, always warrants workup. Refer to hepatology for alanine aminotransferase >500.

Back to Table of Contents

Interpretation by Magnitude of Alanine Aminotransferase Elevation

The magnitude of alanine aminotransferase elevation correlates roughly with the type of underlying liver pathology, providing a useful clinical heuristic:

• Mild elevation (1-2x ULN; ALT 40-80 U/L): Most commonly non-alcoholic fatty liver disease, mild drug-induced liver injury (statins, acetaminophen, anti-tuberculosis agents), chronic viral hepatitis (hepatitis B virus (HBV), hepatitis C virus (HCV)) in the inactive or low-replication phase, alcoholic liver disease (early), autoimmune hepatitis (mild), hemochromatosis, alpha-1 antitrypsin deficiency, Wilson disease (rarely).
• Moderate elevation (2-10x ULN; ALT 80-400 U/L): Active chronic viral hepatitis, moderate-severe non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH), autoimmune hepatitis with active inflammation, moderate drug-induced liver injury, alcoholic hepatitis (typically with aspartate aminotransferase > alanine aminotransferase), early acute viral hepatitis (rising phase).
• Marked elevation (10-25x ULN; ALT 400-1000 U/L): Acute viral hepatitis (peak phase), severe drug-induced liver injury, autoimmune hepatitis with severe inflammation, acute ischemic hepatitis (typically very high aspartate aminotransferase > alanine aminotransferase). Begin hepatology consultation.
• Massive elevation (>25x ULN; ALT >1000 U/L): The differential narrows to three principal causes: (1) acute viral hepatitis (HAV, HBV, occasionally HEV), (2) severe drug-induced liver injury (most classically acetaminophen overdose), and (3) ischemic hepatitis (shock liver). Acetaminophen toxicity in particular can produce alanine aminotransferase in the 5000-10000 U/L range, often the highest values seen in clinical practice. Urgent hepatology consultation. Assess for fulminant hepatic failure (international normalized ratio (INR), encephalopathy).

The rate of change of alanine aminotransferase is also informative. Acute hepatitis typically rises over days and then falls predictably as the injury resolves. Chronic liver disease typically shows stable mildly-elevated values over months. A sudden rise in a previously stable alanine aminotransferase prompts workup for a new injury (drug, infection, ischemic event).

Back to Table of Contents

The Aspartate Aminotransferase:Alanine Aminotransferase Ratio — Alcoholic vs Non-Alcoholic Patterns

The ratio of aspartate aminotransferase to alanine aminotransferase (often written as aspartate aminotransferase/alanine aminotransferase or De Ritis ratio after the Italian biochemist who first proposed it in 1957) provides important diagnostic information about the underlying liver process:

• Aspartate aminotransferase:alanine aminotransferase < 1 (more alanine aminotransferase than aspartate aminotransferase): The pattern of most non-alcoholic liver disease. Found in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (typically 0.7-1.0), chronic viral hepatitis (B and C in the chronic phase), acute viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, hemochromatosis. This is the "default" hepatocellular pattern.
• Aspartate aminotransferase:alanine aminotransferase > 2 (twice as much aspartate aminotransferase as alanine aminotransferase): Strongly suggestive of alcoholic liver disease. The classic Cohen-Kaplan 1979 paper established that aspartate aminotransferase:alanine aminotransferase > 2 has a positive predictive value of approximately 80% for alcoholic etiology in the setting of liver disease. The mechanism involves chronic alcohol-induced depletion of pyridoxal-5-phosphate (vitamin B6), which reduces both alanine aminotransferase and aspartate aminotransferase synthesis but reduces alanine aminotransferase more (alanine aminotransferase has a stricter B6 dependence) — so the ratio shifts toward aspartate aminotransferase dominance.
• Aspartate aminotransferase:alanine aminotransferase > 1 (but < 2): A "gray zone" that includes early cirrhosis from any cause (the aspartate aminotransferase:alanine aminotransferase ratio rises as cirrhosis progresses regardless of the original etiology), non-alcoholic steatohepatitis-related cirrhosis, and a mix of alcoholic and non-alcoholic disease.
• Aspartate aminotransferase:alanine aminotransferase > 4-5 (very high): Suggests acute Wilson disease with hemolysis, severe alcoholic hepatitis, or muscle injury contaminating the test (rhabdomyolysis would also show very high creatine kinase).

The Williams-Hoofnagle 1988 Gastroenterology paper expanded the diagnostic value of the aspartate aminotransferase:alanine aminotransferase ratio specifically for cirrhosis assessment: as liver disease progresses from chronic active inflammation to cirrhosis, the aspartate aminotransferase:alanine aminotransferase ratio rises regardless of the original etiology. A non-alcoholic steatohepatitis patient who starts with aspartate aminotransferase:alanine aminotransferase of 0.7 may have aspartate aminotransferase:alanine aminotransferase of 1.4 by the time non-alcoholic steatohepatitis-related cirrhosis develops. This makes serial aspartate aminotransferase:alanine aminotransferase trending useful for monitoring chronic liver disease progression.

The clinical use of the De Ritis ratio is therefore twofold: (1) initial differential diagnosis of acute or chronic liver disease (alcoholic vs non-alcoholic, principally), and (2) monitoring chronic liver disease progression toward cirrhosis. Both uses are based on the same biochemistry — the differential B6-cofactor dependence of alanine aminotransferase vs aspartate aminotransferase, modulated by the underlying disease's effect on hepatic protein synthesis.

Back to Table of Contents

Non-Alcoholic Fatty Liver Disease — The Global Liver Disease Epidemic

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic-dysfunction-associated steatotic liver disease (MASLD) in the 2023 multi-society consensus, has become the leading cause of chronic liver disease worldwide. The Younossi 2016 Hepatology meta-analysis estimated global prevalence at approximately 25% of adults, with substantial regional variation: about 32% in South America, 27% in Asia, 24% in North America, 24% in Europe, and 31% in the Middle East. In the United States, the National Health and Nutrition Examination Survey (NHANES) data suggest that 30-40% of adults have hepatic steatosis on imaging, of whom an estimated 5-10% have progressed to the more severe non-alcoholic steatohepatitis (NASH) with active inflammation and fibrosis.

Non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease is best understood as the hepatic manifestation of metabolic syndrome — the cluster of central obesity, insulin resistance, atherogenic dyslipidemia, hypertension, and type 2 diabetes that has become the dominant chronic disease pattern in developed and rapidly developing economies. The pathophysiology involves:

1. Excess hepatic fatty acid delivery — from dietary fat, from de novo lipogenesis driven by chronic hyperinsulinemia, and from accelerated lipolysis of insulin-resistant visceral adipose tissue. The hepatocyte's capacity to package and export triglyceride as very-low-density lipoprotein (VLDL) is exceeded.
2. Hepatic triglyceride accumulation — visible as macrovesicular steatosis on biopsy and as hepatic steatosis on ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) elastography.
3. Lipotoxicity-induced hepatocyte injury — the accumulated free fatty acids, diacylglycerols, and ceramides activate inflammatory cytokine production and apoptotic pathways. Cell death releases alanine aminotransferase into the circulation.
4. Hepatic stellate cell activation — the wound-healing response to chronic hepatocyte injury produces collagen deposition and progressive fibrosis. Over years to decades, this can progress to cirrhosis.

Alanine aminotransferase elevation is the most accessible biochemical signal of this process, but alanine aminotransferase has poor sensitivity for non-alcoholic fatty liver disease. The Mofrad 2003 study famously documented histologically severe non-alcoholic fatty liver disease with normal alanine aminotransferase values in approximately 20% of non-alcoholic fatty liver disease patients. The implication is that a normal alanine aminotransferase does not exclude non-alcoholic fatty liver disease — imaging (ultrasound, MRI-PDFF, or transient elastography) is needed when the clinical suspicion is high (body mass index > 30, type 2 diabetes, metabolic syndrome features).

Management of non-alcoholic fatty liver disease is currently behavioral and pharmacological:

• Weight loss — the single most effective intervention. A 5% body weight loss reverses steatosis in most patients; 7-10% loss can reverse early fibrosis.
• Mediterranean diet — emphasizing whole foods, olive oil, fish, vegetables; modest carbohydrate restriction; minimization of fructose-containing sweetened beverages.
• Regular aerobic exercise — independent benefit beyond the weight loss effect.
• Pharmacological options — pioglitazone (an insulin sensitizer with proven non-alcoholic steatohepatitis benefit), glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide and tirzepatide both show significant non-alcoholic steatohepatitis improvement), and resmetirom (recently U.S. Food and Drug Administration-approved specifically for non-alcoholic steatohepatitis with fibrosis).

For more on non-alcoholic fatty liver disease, see our pages on Metabolic Syndrome and Liver Disease.

Back to Table of Contents

Drug-Induced Liver Injury (DILI)

Drug-induced liver injury is the most common cause of acute liver failure in the developed world and a frequent cause of elevated alanine aminotransferase. Hundreds of medications and herbal products have been implicated. The patterns of injury fall into three principal categories:

• Hepatocellular pattern — alanine aminotransferase predominantly elevated relative to alkaline phosphatase. Suggests injury to hepatocytes. Classic offenders: acetaminophen overdose (highest alanine aminotransferase seen in clinical practice), isoniazid, statins, methotrexate, valproate, kava, green tea extract at high doses.
• Cholestatic pattern — alkaline phosphatase predominantly elevated relative to alanine aminotransferase. Suggests injury to biliary epithelium or impaired bile flow. Classic offenders: amoxicillin-clavulanate, anabolic steroids, chlorpromazine, erythromycin estolate, oral contraceptives.
• Mixed pattern — both alanine aminotransferase and alkaline phosphatase elevated, often with the R-value (ALT/ULN divided by ALP/ULN) between 2 and 5. Classic offenders: phenytoin, sulfonamides, carbamazepine.

Specific medications worth knowing:

• Acetaminophen — the most common cause of drug-induced acute liver failure in the United States. Toxicity occurs at doses above 4 g/day (acute), or above 2-3 g/day chronically in heavy alcohol users. Alanine aminotransferase peaks at 48-72 hours after ingestion, often in the thousands to tens of thousands. N-acetylcysteine (NAC) is the antidote when given within 8-10 hours of ingestion.
• Statins — mild alanine aminotransferase elevations in 1-3% of users. The Cohen-Anania-Chalasani 2006 hepatologist consensus established that mild statin-associated alanine aminotransferase elevation is not a contraindication to continued therapy in patients without underlying liver disease; it is a marker rather than a clinically meaningful injury. Severe statin hepatotoxicity is rare.
• Isoniazid — alanine aminotransferase elevation in up to 20% of treated patients, with clinical hepatitis in 0.5-2%. Monthly LFT monitoring is standard during anti-tuberculosis therapy.
• Anabolic steroids — produce a distinctive cholestatic pattern with characteristic bile duct injury. Sometimes overlooked in young athletic men presenting with jaundice.
• Herbal hepatotoxins — kava, green tea extract (high-dose), comfrey, germander, chaparral, pyrrolizidine alkaloid-containing herbs (e.g., some bush teas). Underrecognized cause of unexplained alanine aminotransferase elevation; always take a detailed herbal and supplement history.

The standard approach to suspected DILI is the modified Roussel-Uclaf Causality Assessment Method (RUCAM), which scores the temporal relationship, exclusion of other causes, risk factors, response to dechallenge, and prior knowledge of hepatotoxicity to estimate the probability that a specific agent caused the observed injury.

Back to Table of Contents

Viral Hepatitis Pattern

Viral hepatitis remains an important cause of alanine aminotransferase elevation worldwide. The clinical context and serology determine the workup:

• Hepatitis A (HAV) — acute self-limited infection, fecal-oral transmission, peak alanine aminotransferase typically 1000-3000 U/L. Confirmed by anti-HAV immunoglobulin M (IgM). No chronic phase, no specific antiviral treatment, supportive care only. Vaccine-preventable.
• Hepatitis B (hepatitis B virus) — acute or chronic infection, blood/sexual transmission, alanine aminotransferase pattern varies by phase. Chronic hepatitis B virus may have alanine aminotransferase in the normal range during the immune-tolerant phase, mildly elevated during active replication, and very high during reactivation or HBeAg seroconversion. Confirmed by HBsAg (chronic carrier), anti-HBs (immunity), anti-HBc immunoglobulin M (IgM) (acute infection). Vaccine-preventable. Multiple effective antivirals available.
• Hepatitis C (hepatitis C virus) — usually chronic infection, blood-borne transmission, often mild alanine aminotransferase elevation or even normal alanine aminotransferase. Confirmed by anti-HCV antibody and HCV RNA PCR. Curable in >95% of cases with 8-12 weeks of direct-acting antiviral therapy (sofosbuvir-velpatasvir or glecaprevir-pibrentasvir).
• Hepatitis D (HDV) — defective virus that requires HBsAg coexpression. Test only when HBsAg-positive.
• Hepatitis E (HEV) — fecal-oral or zoonotic transmission, acute self-limited in most cases but can be devastating in pregnancy. Confirmed by anti-HEV immunoglobulin M and polymerase chain reaction (PCR).
• Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus — can produce mild-to-moderate transient alanine aminotransferase elevations during acute viral syndromes. Usually presents with characteristic clinical features (fever, lymphadenopathy, atypical lymphocytosis).

The standard initial viral panel for an unexplained alanine aminotransferase elevation is HBsAg, anti-HCV, and (in appropriate clinical settings) anti-HAV immunoglobulin M and anti-HIV.

Back to Table of Contents

Practical Workup of an Isolated Alanine Aminotransferase Elevation

The Kwo 2017 ACG Clinical Guideline and the Newsome 2018 BSG guideline both provide structured approaches to the patient with an isolated alanine aminotransferase elevation. A practical synthesis:

1. Confirm and characterize — repeat the LFTs to ensure the elevation is real and not laboratory artifact. Calculate the aspartate aminotransferase:alanine aminotransferase ratio and the R-value (ALT/ULN ÷ ALP/ULN). Check international normalized ratio and albumin for synthetic function assessment.
2. History — alcohol intake (use AUDIT-C), medication and herbal supplement use, intravenous (IV) drug use risk factors, sexual risk factors, travel history, family history of liver disease, occupational exposures, prior episodes of jaundice, autoimmune disease history.
3. Physical examination — body mass index and waist circumference (metabolic syndrome), stigmata of chronic liver disease (palmar erythema, spider angiomata, gynecomastia, ascites, splenomegaly), Kayser-Fleischer rings (Wilson disease), arthritis (autoimmune hepatitis association).
4. First-tier laboratory workup — metabolic panel (fasting glucose, hemoglobin A1c, lipid panel for non-alcoholic fatty liver disease risk stratification), HBsAg, anti-HCV, ferritin and transferrin saturation (hemochromatosis), antinuclear antibody (ANA) and ASMA (autoimmune hepatitis), tissue transglutaminase immunoglobulin A (IgA) (celiac).
5. Imaging — abdominal ultrasound for hepatic steatosis, biliary tree, and any focal lesions. MRI-PDFF if quantitative steatosis assessment is needed. Transient elastography (FibroScan) if fibrosis assessment is needed (non-alcoholic fatty liver disease >F2 fibrosis is a hepatology referral trigger).
6. Second-tier workup if first-tier negative — ceruloplasmin and 24-hour urinary copper (Wilson disease), alpha-1 antitrypsin level and Pi typing (alpha-1 antitrypsin deficiency), thyroid function (hypothyroidism-associated non-alcoholic fatty liver disease), human immunodeficiency virus (HIV) testing, repeat viral hepatitis panel including HEV in appropriate clinical contexts.
7. Specialty referral — alanine aminotransferase > 5x ULN despite negative initial workup; persistent alanine aminotransferase elevation >6 months without identified cause; any patient with cirrhosis or significant fibrosis (non-alcoholic fatty liver disease >F2); fulminant presentation (rising international normalized ratio, encephalopathy, jaundice).
8. Liver biopsy — rarely needed in modern hepatology due to advances in non-invasive imaging and serological scoring. Indicated when the diagnosis remains unclear after the second-tier workup, or when management decisions require histological staging.

The most common ultimate diagnosis for an isolated mildly-elevated alanine aminotransferase in a developed-world primary care population is non-alcoholic fatty liver disease, followed by chronic viral hepatitis (B or C), alcoholic liver disease, drug-induced injury, and autoimmune hepatitis. The rarer diagnoses (Wilson disease, alpha-1 antitrypsin deficiency, hemochromatosis) should be specifically considered in younger patients without obvious metabolic or behavioral risk factors.

Back to Table of Contents

The Alanine Load Test for Hepatic Function

The alanine load test is a research-grade assessment of hepatic functional reserve that uses an oral alanine dose (15-30 g) to challenge the gluconeogenic capacity of the liver. The post-load plasma glucose and alanine kinetics provide a sensitive measure of hepatic gluconeogenic capacity that is impaired earlier than conventional liver function markers.

In healthy subjects, oral alanine produces a brisk rise in plasma alanine peaking at 60-90 minutes, with proportional plasma glucose rise and glucagon secretion. The plasma alanine clearance half-life is approximately 90 minutes. The test was originally developed by Genuth and Castro in the 1970s for assessing fasting and obesity physiology, and subsequently adapted for research evaluation of hepatic function in cirrhosis, non-alcoholic steatohepatitis, and post-bariatric patients.

The alanine load test is rarely used in routine clinical hepatology because non-invasive imaging (magnetic resonance imaging elastography, FibroScan) and validated scoring systems (FIB-4, non-alcoholic fatty liver disease Fibrosis Score, APRI) provide more practical assessments of hepatic function and fibrosis. The test remains useful in research settings where dynamic gluconeogenic capacity is the specific question of interest.

For patients curious about alanine's metabolic role in their own physiology, the clinical correlate is simpler: a standard glucose tolerance test (oral 75 g glucose with serial glucose and insulin measurements) implicitly assesses the post-load alanine response as part of the integrated postprandial metabolic state. Reactive hypoglycemia identified on a glucose tolerance test often reflects impaired alanine-mediated gluconeogenic counter-regulation.

Back to Table of Contents

Cautions

• An isolated mildly elevated alanine aminotransferase is common and often benign — 20-30% of US adults have alanine aminotransferase above the Prati cutoffs. Most have non-alcoholic fatty liver disease that improves substantially with weight loss and Mediterranean diet. Not every mildly elevated alanine aminotransferase requires aggressive workup; clinical context is everything.
• Normal alanine aminotransferase does not exclude significant liver disease — up to 20% of non-alcoholic fatty liver disease patients with significant histological injury have normal alanine aminotransferase (Mofrad 2003). Imaging is more sensitive than alanine aminotransferase for steatosis.
• Pyridoxal-5-phosphate (vitamin B6) deficiency lowers alanine aminotransferase — chronic alcohol abuse, malnutrition, and isoniazid use can all deplete B6 and produce artifactually low alanine aminotransferase values. This is part of the mechanism behind the aspartate aminotransferase:alanine aminotransferase > 2 pattern of alcoholic liver disease.
• Pregnancy lowers alanine aminotransferase — physiological dilution of plasma proteins during pregnancy reduces alanine aminotransferase activity by approximately 25%. A pregnant woman's alanine aminotransferase should be interpreted against pregnancy-specific reference ranges.
• Acetaminophen safety — do not exceed 4 g/day total in healthy adults, and limit to 2-3 g/day in regular alcohol users. Read all combination products carefully (many cold medicines and prescription pain medications contain acetaminophen and easily accumulate to toxic doses when stacked).
• Herbal supplement screening — take a detailed history including all over-the-counter and herbal products in any patient with unexplained alanine aminotransferase elevation. Kava, green tea extract at high doses, comfrey, chaparral, and pyrrolizidine alkaloid-containing teas are well-documented hepatotoxins.
• Heavy exercise within 48 hours of blood draw — can artifactually elevate both alanine aminotransferase and aspartate aminotransferase through muscle origin. If exercise is suspected as the cause, repeat the LFTs after 1 week of exercise abstinence.
• L-alanine supplementation does not affect alanine aminotransferase in any clinically meaningful way — the enzyme is constitutively expressed at very high levels; substrate availability is not rate-limiting under normal physiological conditions. Routine L-alanine supplements are not a treatment for elevated alanine aminotransferase, nor a cause of it.

Back to Table of Contents

Key Research Papers

1. Pratt DS, Kaplan MM (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. NEJM 342(17):1266-1271. — DOI: 10.1056/NEJM200004273421707. — doi:10.1056/NEJM200004273421707
2. Prati D, Taioli E, Zanella A, et al. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine 137(1):1-10. — DOI: 10.7326/0003-4819-137-1-200207020-00006. — doi:10.7326/0003-4819-137-1-200207020-00006
3. Kwo PY, Cohen SM, Lim JK (2017). ACG Clinical Guideline: Evaluation of abnormal liver chemistries. American Journal of Gastroenterology 112(1):18-35. — DOI: 10.1038/ajg.2016.517. — doi:10.1038/ajg.2016.517
4. Newsome PN, Cramb R, Davison SM, et al. (2018). Guidelines on the management of abnormal liver blood tests. Gut 67(1):6-19. — DOI: 10.1136/gutjnl-2017-314924. — doi:10.1136/gutjnl-2017-314924
5. Younossi ZM, Koenig AB, Abdelatif D, et al. (2016). Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment. Hepatology 64(1):73-84. — DOI: 10.1002/hep.28431. — doi:10.1002/hep.28431
6. Cohen JC, Horton JD, Hobbs HH (2011). Human fatty liver disease: old questions and new insights. Science 332(6037):1519-1523. — DOI: 10.1126/science.1204265. — doi:10.1126/science.1204265
7. Mofrad P, Contos MJ, Haque M, et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37(6):1286-1292. — DOI: 10.1053/jhep.2003.50229. — doi:10.1053/jhep.2003.50229
8. Williams ALB, Hoofnagle JH (1988). Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis — relationship to cirrhosis. Gastroenterology 95(3):734-739. — DOI: 10.1016/s0016-5085(88)80022-2. — doi:10.1016/s0016-5085(88)80022-2
9. Cohen JA, Kaplan MM (1979). The SGOT/SGPT ratio — an indicator of alcoholic liver disease. Digestive Diseases and Sciences 24(11):835-838. — DOI: 10.1007/BF01324898. — doi:10.1007/BF01324898
10. Sookoian S, Pirola CJ (2012). Alanine and aspartate aminotransferase and glutamine-cycling pathway in NAFLD. World Journal of Gastroenterology 18(29):3775-3781. — DOI: 10.3748/wjg.v18.i29.3775. — doi:10.3748/wjg.v18.i29.3775
11. Cohen DE, Anania FA, Chalasani N (2006). An assessment of statin safety by hepatologists. American Journal of Cardiology 97(8A):77C-81C. — DOI: 10.1016/j.amjcard.2005.12.014. — doi:10.1016/j.amjcard.2005.12.014
12. Larson AM, Polson J, Fontana RJ, et al. (2005). Acetaminophen-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 42(6):1364-1372. — DOI: 10.1002/hep.20948. — doi:10.1002/hep.20948
13. Chalasani N, Younossi Z, Lavine JE, et al. (2018). The diagnosis and management of NAFLD: practice guidance from AASLD. Hepatology 67(1):328-357. — DOI: 10.1002/hep.29367. — doi:10.1002/hep.29367
14. Genuth SM, Castro J (1974). Effect of oral alanine administration in fasting obese subjects. Metabolism 23(4):375-386. — PubMed

PubMed Topic Searches

1. PubMed: ALT and liver function testing
2. PubMed: AST:ALT (De Ritis) ratio in liver disease
3. PubMed: NAFLD/NASH and ALT
4. PubMed: Drug-induced liver injury (DILI)
5. PubMed: Prati healthy ALT cutoffs
6. PubMed: Acetaminophen hepatotoxicity

Back to Table of Contents

Connections

• All Amino Acids
• Alanine Overview
• Alanine Benefits Hub
• Alanine for Gluconeogenesis & Blood Sugar
• Beta-Alanine for Endurance
• Alanine for Immune Function
• Glutamic Acid (Transamination Partner)
• Glutamine
• Vitamin B6 (Alanine Aminotransferase Cofactor)
• Liver Disease
• Metabolic Syndrome (Non-Alcoholic Fatty Liver Disease)
• Diabetes (Non-Alcoholic Fatty Liver Disease)
• Obesity (Non-Alcoholic Fatty Liver Disease)
• Lab Tests
• N-Acetylcysteine (Acetaminophen Antidote)
• Liver Cleanse
• Milk Thistle
• History
• Sources

Back to Table of Contents

×

Featured Videos